Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

Agomab Therapeutics (Group)

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. By combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases. Agomab’s pipeline of growth factor targeting antibodies and small molecule compounds includes its lead candidate AGMB-129, a gastrointestinal tract restricted ALK5 inhibitor for which it has recently started a Phase 2a clinical trial in Fibrostenosing Crohn’s Disease and received U.S. FDA Fast Track Designation. The second TGFß targeting pipeline candidate, AGMB-447, is a Phase-1-ready lung-restricted ALK5-inhibitor for treatment of idiopathic pulmonary fibrosis. AGMB-101 is an HGF-mimetic cMET receptor agonist in IND-enabling development for the treatment of fibrotic disorders. *

 

Period Start 2017-01-01 established
Products Industry growth factor-mimetic agonistic monoclonal antibody (agomAb)
  Industry 2 SIMPLE Antibody™ discovery platform
Persons Person Knotnerus, Tim (AgomAb Therapeutics 201904c– CEO before AM-Pharma + Aescap Venture)
  Person 2 Hassan, Tolga (AgomAb Therapeutics 202103– CFO before F-Star + Johnson Matthey)
     
Region Region Gent (Ghent)
  Country Belgium
  Street 2/104 Pieter Van Reysschootlaan
  City 9051 Gent
    Address record changed: 2021-10-31
     
Basic data Employees n. a.
     
    * Document for »About Section«: Agomab Therapeutics N.V.. (10/10/23). "Press Release: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline". Ghent.
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Agomab Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top